| ID | 1236 |
| Name of the vaccine | ID93 + GLA-SE |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 19 to 64 years |
| Description of the vaccine | ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). |
| Name of the manufacturer | Quratis Inc. |
| Name of the manufacturing country | Korea, Republic of |
| Year of manufacture | 2020 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses, one month apart. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | GLA-SE |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03806686 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|